POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV (BIT225-010)
Preliminary analyses indicate that the primary objectives of the trial have been met.
The results suggest that BIT225 is having a unique effect beyond that seen with current standard of
care antiretroviral drugs.
The data is consistent with BIT225 targeting virus present in reservoir cells.
